Quantcast
Last updated on April 21, 2014 at 5:21 EDT

Latest Vascular endothelial growth factor Stories

2013-10-21 08:28:31

TARRYTOWN, N.Y., Oct. 21, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results for EYLEA(®) (aflibercept) Injection from the Phase 3 VIBRANT study in patients with Macular Edema following Branch Retinal Vein Occlusion (BRVO). In this trial, 53% of patients who received EYLEA 2 milligram (mg) every four weeks gained at least 15 letters in vision from baseline at week 24, the primary endpoint of the study, compared to 27% of...

2013-10-09 12:08:08

A team of researchers at Georgetown University Medical Center (GUMC) has found that loss of an anti-aging gene induces retinal degeneration in mice and might contribute to age-related macular degeneration, the major cause of blindness in the elderly. In the Oct. 9 issue of the Journal of Neuroscience, the scientists demonstrated a key role for the aging-suppressor gene Klotho in maintaining the health of the mouse and human retina. They say that in their animal studies, loss of Klotho...

2013-10-03 09:31:58

The phase III study published in the The Lancet shows that an antibody (ramucirumab) inhibits the action of various proteins involved in tumor growth, prolonging survival of patients with advanced gastric cancer This international trial, published in The Lancet, is one of the largest phase III trials in second-line treatment of gastric cancer. Standard care for advanced gastric cancer, known as first-line treatment, is based on chemotherapy, but it only offers a median survival of 8 to 10...

2013-09-30 15:52:49

Women with ovarian cancer that has recurred after chemotherapy have survived for longer after treatment with a biological therapy called cediranib, according to new results to be presented today (Monday) at the 2013 European Cancer Congress (ECC2013). Cediranib, which is taken in pill form, is an inhibitor of a cell signalling process involved in formation of tumour blood vessels, essential for tumour growth, and it is the first oral inhibitor of its kind to show an improvement in the time...

2013-09-26 08:28:14

Encouraging activity seen in first patient cohort to be confirmed in trial expansion CAMBRIDGE, Mass., Sept. 26, 2013 /PRNewswire/ -- Cerulean Pharma Inc., a leader in dynamically tumor-targeted nanopharmaceuticals, today announced that the combinability of CRLX101 and Avastin has been established in a Phase 1b/2a clinical trial studying the use of this combination to treat patients with metastatic renal cell carcinoma (mRCC). Patients treated with CRLX101 and Avastin(®) at their...

2013-09-26 08:26:57

Exhibiting at the 13th Euretina Congress, the Angiogenesis Foundation invites visitors to explore its new multimedia resources on diabetic macular edema and central retinal vein occlusion. HAMBURG, Germany, Sept. 26, 2013 /PRNewswire/ -- The nonprofit Angiogenesis Foundation today launched two novel multimedia campaigns--the Science of DME and the Science of CRVO-- at the 13(th) Euretina Congress in Hamburg, Germany. These campaigns address the knowledge gap for two of the world's common...

2013-09-25 04:22:12

SOUTHAMPTON, England, September 25, 2013 /PRNewswire/ -- Consortium supported by EU Seventh Framework Programme KalVista Pharmaceuticals ("KalVista"), an ophthalmology company with a focus on diabetic macular edema (DME), is joining a group of academic and industry researchers to undertake a project known as '3D-NET' ('Drug Discovery and Development of Novel Eye Therapeutics'). The four-year project seeks to enable the development of new drugs for the treatment of...

2013-09-17 16:23:57

TARRYTOWN, N.Y., Sept. 17, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that detailed results from the Phase 3 VIVID and VISTA trials of EYLEA(®) (aflibercept) Injection in Diabetic Macular Edema (DME) will be presented at an oral session during the upcoming annual meeting of the Retina Society to be held September 26-29 in Los Angeles, United States. These data will be presented on Friday, September 27, at 4:51 PM PDT. Separately, these data...

Cancer Drug To Treat Diabetes
2013-09-16 12:07:11

Brett Smith for redOrbit.com - Your Universe Online New research from a team of American scientists has identified both a biochemical pathway involved in the development of diabetes and a drug already approved by the FDA for the treatment of cancer that is capable of regulating that pathway. Findings from the research were published as two separate online articles in Nature Medicine on Sunday. After a meal, blood glucose levels increase and insulin causes cells in the liver to store...

Macular Degeneration Treatment Hope
2013-09-15 04:15:49

Brett Smith for redOrbit.com - Your Universe Online According to a new study published in the Journal of Clinical Investigation, medical researchers at the University of North Carolina are developing a promising new treatment for macular degeneration. Based on experiments with laboratory mice, a group of drugs known as MDM2 inhibitors proved exceedingly effective at mitigating the abnormal blood vessels responsible for the vision loss linked to the disease. “We believe we may have...